Krakow, Poland – 4 April 2019 – Selvita, drug discovery and development partner for the pharmaceutical and biotechnology industries, will exhibit at the upcoming 14th Annual Drug Discovery Chemistry conference, taking place 8-12 April at the San Diego Convention Center, in San Diego, US.

Throughout the whole event, Selvita’s team will be available at booth #102, to discuss Selvita’s capabilities in the area of integrated drug discovery services, and potential collaborations.

To contact Selvita’s delegates at this conference, please email us at [email protected]

Cambridge Healthtech Institute’s 14th Annual Drug Discovery Chemistry is a dynamic conference for medicinal chemists working in pharma and biotech. Focused on discovery and optimization challenges of small molecule drug candidates, this event provides many exciting opportunities for scientists to create a unique program to hear presentations most suited to one’s personal interests by going back and forth among concurrent conferences. New for 2019 includes coverage of Artificial Intelligence for Early Drug Discovery and Directed Evolution-Based Drug Discovery.

Additional information is available on the conference website at

Selvita Services Division

Selvita Services Division is a drug discovery and development partner for the pharmaceutical and biotechnology industries. It provides integrated drug discovery support starting from hit identification, hit to lead, lead optimization phase, up to nomination of a preclinical candidate. The broad range of services includes medicinal and computational chemistry, custom synthesis and scale-up, in vitro pharmacology, structural biology, protein chemistry, ADME/DMPK as well as a comprehensive offer of analytical testing for APIs and drug products. In addition, Selvita Services Division has extensive expertise in comparability studies of biosimilar drugs. Its laboratories are both GLP- and GMP-certified.

About Selvita

Selvita S.A. is a clinical stage drug discovery company engaged in the research and development of novel cancer therapies, as well as provision of integrated drug discovery services. Selvita is headquartered in Krakow, Poland, with offices in the U.S (Greater Boston, San Francisco Bay), and in the U.K. (Cambridge). Selvita has currently several projects at early or late discovery stage. Drug discovery clients of Selvita include numerous large and medium-sized pharmaceutical and biotechnology companies from the U.S. and Europe. The company is listed on the Warsaw Stock Exchange (WSE:SLV).


Natalia Baranowska
+48 784 069 418
[email protected]